Your Messages Inbox
Your Article Summary
See Latest ArticlesVectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Amgen, 09/25/09
Amgen announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) administered in combination with FOLFOX as the first–line treatment of metastatic colorectal cancer. In this trial, Vectibix significantly improved median progression–free survival by 1.6 months in patients with KRAS wild–type mCRC.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Primary endpoint reached in Active Biotechs TASQ Phase II clinical trial in prostate cancer patients
Active Biotech, 12/15/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
Genentech, 12/15/09
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline, 12/15/09
Article Search
Sponsor